IQVIA Holdings Inc. stock falls 1.46% and underperforms sector rivals

9 articles · Updated · MarketWatch · Apr 29

Shares closed at $156.66 on Wednesday, marking a second consecutive day of losses and trading 36.59% below their 52-week high of $247.05.
IQVIA's decline contrasted with gains for competitors like HCA Healthcare and Centene, while Labcorp also slipped. Trading volume was 1.5 million, below the 50-day average of 1.8 million.
The broader market also struggled, with the S&P 500 and Dow Jones both declining. IQVIA continues to lag behind sector peers amid ongoing market volatility.

While competitor Centene soars, what is holding back IQVIA's stock performance?

Is IQVIA's 36% stock plunge a major warning sign or a buying opportunity?

Is IQVIA's major bet on AI enough to fight the healthcare sector's downturn?

How will new federal healthcare spending cuts impact IQVIA's growth pipeline?

Can a new obesity research deal reverse IQVIA's sharp market decline?